Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q1 FY24 Earnings Presentation
30 slides from Gufic Biosciences's earnings presentation, August 2023
Slide 1: Delivering Care & Cure: Investor Presentation
Delivering Care & Cure Investor Presentation August 2023
Slide 2: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions. This prese ntation does not constitute or form part of any offer or invitation
Slide 3: Q1 FY24 Business & Financial Highlights
Q1 FY24 Business & Financial Highlights
Slide 4: Q1 FY24 Business Highlights
Q1 FY24 Business Highlights Gearing up for Indore Facility to go live Domestic Business Breakup • R&D Advancements: Our investment in R&D for molecules at the Indore facility continues to yield promising results, enhancing our product pipeline Critical Care Division • Time-to-Market Efficiency: Our
Slide 5: Q1 FY24 Business Highlights
Q1 FY24 Business Highlights • Advancements in Immunocin-Alpha: Trials for sepsis involving Immunocin-Alpha have concluded successfully. We anticipate DCGI approval by Q3, underscoring our commitment to pioneering advancements in critical care • Venturing into Total Parenteral Nutrition Market: We ar
Slide 6: Q1 FY24 Business Highlights
Q1 FY24 Business Highlights Healthcare, Stellar & Spark Division • Multivitamin Success and Mass Market Enhancement: The successful launch of a new zinc-based multivitamin has been warmly received in the market. This strategic addition has not only expanded our portfolio but has also bolstered our p
Slide 7: Q1 FY24 Business Highlights
Q1 FY24 Business Highlights Arisia, The Center of Excellence • Elevating Aesthetic Excellence in Mumbai: Introducing Arisia, our Center of Excellence in Mumbai—a cutting-edge aesthetic clinic and training center that redefines the benchmarks for excellence in aesthetic care. Arisia is meticulously d
Slide 8: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 9: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 10: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q1 FY24 Q1 FY23 FY23 To ta l Rev e n u e 195.0 165.3 690.6 E B I T DA 36.4 33.6 137.2 E B I T DA M a r g i n % 18.6% 20.3% 19.9% P ro f i t b efo re Ta x 28.0 28.3 106.7 P BT M a r g i n s % 14.4% 17.1% 15.5% Ta x 7.4 7.2 27.0 P r o f
Slide 11: Company Overview
Company Overview
Slide 12: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 13: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 14: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Validation Milestone: Validation of the Indore facility is Facility Carbapenems (Lyophilized / Dry on track for completion by Septembe
Slide 15: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 16: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 17: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 18: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 19: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 20: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 21: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 22: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 23: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 24: Historical Financials
Historical Financials
Slide 25: Historical Financials
Historical Financials Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin 13.1% 13.8% 17.2% 19.4% 19.9% 5.4% 6.3% 6.0% 12.3% 11.5% 779 691 151 96 137 488 80 379 351 84 44 52 46 22 23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22 FY23 CAGR 18% CAGR 31% CAGR 38
Slide 26: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 FY18 Revenue from Operations 690.6 779.2 487.7 378.8 350.8 305.6 EBITDA 137.2 151.1 83.9 52.1 46.0 38.8 EBITDA Margin % 19.9% 19.4% 17.2% 13.8% 13.1% 12.7% Profit before Tax 106.7 126.8 57.7 30.1 35.3 30.0 PBT Margin % 15.5% 16.3%
Slide 27: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 9.7 9.7 9.7 9.7 7.8 Other Equity 338.1 259.4 163.7 119.6 67.6 Total Equity 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liabilities i. Borrowings
Slide 28: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 126.8 105.5 93.8 72.7 24.1 Intangible assets 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 169.6 40.9 13.4 30.6 9.6 Right of use assets 32.1 9.1 5.8 9.3 0.0 Financia
Slide 29: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 106.7 126.9 44.2 22.7 21.9 Adjustments for: Non - Cash Items / Other Investment or 29.6 23.2 44.3 32.1 26.8 Financial Items Operating profit before working capital changes 136.4 150.0 88.5 54.8 48.7 C
Slide 30: Thank You
THANK YOU Company: Gufic Biosciences Limited Investor Relations Advisors: Strategic Growth Advisors (SGA) CIN: L24100MH1984PLC033519 CIN: U74140MH2010PTC204285 Mr. Avik Das – Investor Relations Mr. Deven Dhruva / Mr. Harsh Shah avik.das@guficbio.com deven.dhruva@sgapl.net / harsh.shah@sgapl.net Tel: